

Necker-Pasteur Clinical Metagenomics: Part 2. Contribution to Pathogen Discovery

Philippe Pérot, Béatrice Regnault, Franck Bielle, Jacques Fourgeaud, Éric Troadec, Nicolas da Rocha, Delphine Chrétien, Thomas Bigot, Marianne Leruez-Ville, Agnès Ferroni, et al.

▶ To cite this version:

Philippe Pérot, Béatrice Regnault, Franck Bielle, Jacques Fourgeaud, Éric Troadec, et al.. Necker-Pasteur Clinical Metagenomics: Part 2. Contribution to Pathogen Discovery. 6th International Conference on Clinical Metagenomics, Oct 2021, Geneva, Switzerland. . pasteur-03467165

HAL Id: pasteur-03467165 https://pasteur.hal.science/pasteur-03467165v1

Submitted on 6 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NoDerivatives 4.0 International License

Necker-Pasteur Clinical Metagenomics: Part 2. Contribution to Pathogen Discovery

Philippe Pérot¹, Béatrice Regnault¹, Franck Bielle³, Jacques Fourgeaud², Éric Troadec¹, Nicolas Da Rocha¹, Delphine Chrétien¹, Thomas Bigot¹, Marianne Leruez-Ville², Agnès Ferroni², Danielle Seilhean³, Anne Jamet² & Marc Eloit¹


1. Pathogen Discovery Laboratory, Institut Pasteur, Paris, 75015, France 2. AP-HP, Hôpital Necker-E.M., Microbiologie clinique, Paris, 75015, France 3. AP-HP, Groupe Hospitalier Universitaire Pitié-Salpêtrière, Département de Neuropathologie Raymond Escourolle, Paris, 75013 France


BACKGROUND


Clinical metagenomics fuels pathogen discovery but a comprehensive research environment is required to address critical questions such as imputability, physiopathology of novel identified infectious agents, and development of new diagnostic tools. The Institut Pasteur, in close collaboration with specialized hospital clinical services and laboratories including (neuro)pathologists, along with other academic labs, seeks to address these topics.


METHODS

We present the research environment, including sequencing and analyzing tools, molecular biology, virology, histology and entomology resources, that promotes the exploration of novel or unexpected pathogens identified from patient samples.










RESULTS

We review some of the major identifications done in the course of our historical partnership with hospitals, by highlighting the place and the contribution of research works following identification of new or unexpected microorganisms. The list includes novel human pathogens with a zoonotic potential (Astrovirus VA1, Umbre orthobunyavirus, European Bat Lyssavirus 1) and known pathogens with unexpected or atypical presentation (Rubella virus, Rabies, Dengue).



CONCLUSION

Pathogen discovery includes the identification and characterization of new or unexpected infectious agents and the demonstration of their causality, with the objectives of understanding their biology and fostering the development of novel diagnostic or therapeutic tools. The goal of the Pasteur-Necker initiative in the coming years is to become a national center for clinical metagenomics combining patient care and fundamental research with potential for medical applications, for the benefit of science and patients.







